Drug Profile
Genistein crystalline - Axcentua
Alternative Names: AXP-107 11; genistein sodium salt dihydrate; genistein-SSDHLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Axcentua Pharmaceuticals
- Class Antifibrotics; Antineoplastics; Chemosensitisers; Isoflavones; Osteoporosis therapies; Phytotherapies; Radioprotectives; Small molecules
- Mechanism of Action Apoptosis stimulants; DNA topoisomerase inhibitors; Protein tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Pancreatic cancer
- No development reported Mucopolysaccharidosis III; Solid tumours
Most Recent Events
- 28 May 2018 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-III in Sweden (PO, Capsule)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Solid-tumours in Sweden (PO, Capsule)
- 25 Sep 2015 Phase-I/II development for Pancreatic cancer is ongoing in Sweden